Rev: March, 2025



# Toxocara IgG ELISA

## Toxo-G-96

#### **Intended Use**

The *Toxocara* ELISA test is a semi-quantitative enzyme immunoassay for the detection of antibodies to *Toxocara*, in samples of human serum or plasma. This test is intended to be performed by trained medical technologists only.

# **Summary and Explanation**

Toxocariasis is the infection caused by roundworm of the genus *Toxocara* (usually *T. canis*, rarely *T. cati*) and is acquired by ingesting soil contaminated with embryonated eggs from an animal's feces. These eggs become embryonated after 2 to 5 weeks after being passed by the animal. Thus, human infection does not occur by contact with fresh feces. In addition, infected humans cannot pass the infection to other humans.

The disease manifests itself as visceral larval migrans (VLM) and ocular larval migrans (OLM). Signs and symptoms of VLM may vary from an asymptomatic state with mild eosinophilia to a severe and potentially fatal disorder. Patients with OLM also vary widely in presentation, from acute lesions in the eye to asymptomatic infections. *Toxocara* larva migrans is believed to be the second most common helminth infection in developed countries.

There is no definitive method to diagnose *Toxocara* infections, thus true sensitivity and specificity of serologic tests cannot be accurately determined. The diagnosis is further complicated by the fact that the antibody response varies depending on worm burden and location. However, numerous studies have shown that immunoassays using a purified excretory antigen from the larval stage, as in this ELISA, have shown dramatically improved sensitivities and specificities when compared to assays using crude antigens.

## **Assay Principle**

The microwells are coated with *Toxocara* Excretory antigen. During the first incubation with the diluted patients' sera, any antibodies which are reactive with the antigen will bind to the coated wells. After washing to remove the rest of the sample, the Enzyme Conjugate is added. If antibodies have been bound to the wells, the Enzyme Conjugate will then bind to these antibodies. After another series of washes, a chromogen (tetramethylbenzidine or TMB) is added. If the Enzyme Conjugate is present, the peroxidase will catalyze a reaction that consumes the peroxide and turns the chromogen from clear to blue. Addition of the Stop Solution ends the reaction and turns the blue color to a bright yellow color. The reaction may then be read visually or with an ELISA reader.

## Reagents

Item	Description	Symbol
Test Strips	Microwells containing <i>Toxocara</i> Excretory antigens - 96 test wells in a test strip holder.	MT PLATE
Enzyme Conjugate	One (1) bottle containing 11 ml of Protein-A conjugated to peroxidase.	СОИЈ
Positive Control	One (1) vial containing 2 ml of a surrogate positive control.	CONTROL +
Negative Control	One (1) vial containing 2 ml of diluted human sera.	CONTROL —
Chromogen	One (1) bottle containing 11 ml of the chromogen tetramethylbenzidine (TMB).	SUBS TMB
Wash Concentrate (20X)	Two (2) bottles containing 25 ml of concentrated buffer and surfactant.	WASH BUF
Dilution Buffer	Two (2) bottles containing 30 ml of buffered protein solution.	SPECM DIL
Stop Solution	One (1) bottle containing 11 ml of 1 M phosphoric acid.	SOLN

Toxo-G-96 March 2025

#### **Statement of Warnings**

- **Do not deviate from the specified procedures when performing this assay**. All specimen dilutions, incubation times/temperatures and washings have been optimized for the best performance characteristics. Deviations from the specified procedures may affect the sensitivity and specificity of the assay.
- For In Vitro Diagnostic Use Only.
- Do not interchange reagents between kits with different lot numbers.
- Do not use reagents that are beyond their expiration dates. Expiration dates are on each reagent label. Use of reagents beyond their expiration dates may affect results.
- Unused microwells should be stored in the desiccated pouch to protect them from moisture.
- Do not use solutions if they precipitate or become cloudy.
  - Exception: Wash concentrate may precipitate during refrigerated storage, but will dissolve upon warming.
- Do not add azides to the samples or any of the reagents.
- Controls and some reagents contain Thimerosal as a preservative, which may be irritating to skin, eyes and mucous membranes. In case of contact, flush eyes or rinse skin with copious amounts of water.
- Do not use serum that may have supported microbial growth, or is cloudy due to high lipid content. Samples high in lipids should be clarified before use.
- Treat all reagents and samples as potentially infectious materials. Positive control has been tested and found negative for Hepatitis B surface antigen and for the antibody to HIV be required test methods. Use care to prevent aerosols and decontaminate any spills of samples.
- Stop solution is a 5% solution of phosphoric acid in water. If spilled on the skin, wash with copious amounts of water. If acid gets into the eyes, wash with copious amounts of water and seek medical attention.

#### Storage

- Reagents, strips and bottled components should be stored at 2-8 °C
- Squeeze bottle containing diluted wash buffer may be stored at room temperature (15-25 °C)

#### **Preparation**

- Before use, bring all reagents and samples to room temperature (15-25 °C) and mix.
- (20X) Wash Concentrate may precipitate during refrigerated storage, but will go back into solution when
  brought to room temperature and mixed. *Ensure that (20X) Wash Concentrate is completely in solution*before diluting to working concentration. To dilute (20X) wash concentrate to working dilution, remove cap
  and add contents of one bottle of Wash Concentrate to a squeeze bottle containing 475 ml of DI water. Swirl to
  mix. Squeeze bottle should have a narrow tip to optimize washings.

## **Specimen Collection And Handling**

Serum or plasma may be stored at 2-8  $^{\circ}$ C for up to five days. Sample may be frozen below -20  $^{\circ}$ C for extended periods. Freezing whole blood samples is not advised. Do not heat inactivate samples and avoid repeated freezing and thawing of samples.

#### Procedure

#### **Materials Provided**

Toxocara IgG ELISA Kit

## **Materials Required But Not Provided**

- Micropipette
- Squeeze bottle for washing strips (narrow tip is recommended)
- Reagent grade (DI) water
- Graduated Cylinder
- Sample Dilution Tubes
- Absorbent paper

### **Suggested Materials**

ELISA plate reader with a 450 nm and a 620 - 650 nm filter (optional if results are read visually)

#### **Proper Temperature**

All incubations are at room temperature (15-25 °C)

Toxo-G-96 March 2025

#### **Test Procedure**

#### Notes:

- Ensure all samples and reagents are at room temperature (15-25°C)
- When running the assay, try to avoid the formation of bubbles in the wells. Bubbles may affect overall performance and reading of end results. Slapping the wells out on a clean absorbent towel after each step should help to minimize bubbles in the wells.
- Negative and positive controls are supplied pre-diluted. DO NOT dilute further.
- 1. Break off number of wells needed (two for controls plus number of samples) and place in strip holder.
- Dilute patient sera 1:64 using the Dilution Buffer (e.g. 5 µl sera and 315 µl dilution buffer).
- 3. Add **100 μI** of the negative control to well #1, **100 μI** of the positive control to well #2 and **100 μI** of the diluted test samples to the remaining wells.
- 4. Incubate at room temperature for **10 minutes**, then wash.\* After last wash step, slap the wells on a clean absorbent towel to remove excess wash buffer.
- 5. Add **100 µI** of Enzyme Conjugate to each well.
- 6. Incubate at room temperature for **5 minutes**, then wash.\* After last wash step, slap the wells on a clean absorbent towel to remove excess wash buffer.
- 7. Add **100 µl** of the Chromogen to each well.
- 8. Incubate at room temperature for **5 minutes**.
- Add 100 μI of the Stop Solution to each well. Mix wells by gently tapping the side of the strip holder with index finger for approximately 15 seconds.
- 10. Read within one hour of adding Stop Solution.
- \* Washings consist of vigorously filling each well to overflowing and decanting contents three (3) separate times. If using automated washers; add 1 minute dwell time between washings and increase number of washes from three to five.

### **Reading Results**

Visually: Look at each well against a white background (e.g. paper towel) and record as clear or +, ++ or +++ reaction.

ELISA Reader: Zero reader on air. Set for bichromatic readings at 450/620-650 nm.

## **Quality Control**

The use of controls allows validation of kit stability. The kit should not be used if any of the controls are out of range.

Expected values for the controls are:

**Negative** - 0.0 to 0.1 OD units **Positive** - 0.5 OD units and above

## **Troubleshooting**

Negative control has excessive color after development.

Reason: inadequate washings

**Correction:** wash more vigorously. Remove excessive liquid from the wells by tapping against an Absorbent towel. Do not allow test wells to dry out.

# Interpretation of the Test – ELISA Reader

Zero ELISA reader on air. Read all wells at 450/650-620 nm.

**Positive** – Absorbance reading equal to or greater than 0.2 OD units.

Negative - Absorbance reading less than 0.2 OD units

Toxo-G-96 March 2025

#### **Limitations of The Procedure**

Diagnosis of Toxocara infection should not be made solely based on results of the ELISA Toxocara test alone, but in conjunction with other clinical signs and symptoms and other laboratory findings.

Epidemiologic factors, clinical findings, exposure to endemic regions, and other laboratory results should be considered when making a diagnosis.

## **Expected Values**

The number of antibody positive subjects in a population depends on two factors: disease prevalence and clinical criteria used to select the tested population. Because very few positives should be seen in a randomly screened population in a non-endemic area, most serology tests are not specific enough to screen non-endemic populations. Even in an endemic region, serology screening often yields many false positives if used to randomly screen patients. Serology tests are useful to test patients in an endemic region with signs and symptoms consistent with the disease.

#### **Performance Characteristics**

#### Study #1 - Canadian Reference Center

Compared NLD LLC ELISA kit to another commercial ELISA. Found concordance of 84% (n=82).

Study #2 - Mayo Clinic

Reference Method\*

		+	-
NLD ELISA	+	21	1
	-	3	14

Sensitivity of 87.5% (21/24) Specificity of 93.3% (14/15)

### References

- Glickman, L., P. Schantz, and R. Grieve. "Toxocariasis". Immunodiagnosis of Parasitic Diseases. Vol.1, Helminthic Diseases. Ed. Walls and Schantz. Academic Press, 1986. pp. 201-231.
- 2.
- Schantz, P. "Toxocara Larva Migrans Now." <u>Am J Trop Med Hyg.</u> Vol. 41 (Sup 3), 1989, pp. 21-34. Jacquier, P. et. al. "Immunodiagnosis of Toxocarosis in Humans: Evaluation of a New Enzyme-Linked 3. Immunosorbent Assay Kit." <u>J Clin Micro.</u> Vol. 29 #9, Sept. 1991, pp. 1831-1835.
- Carlier, Y. et. al. "The Use of an Excretory-Secretory Antigen for an ELISA Specific Serodiagnosis of Visceral Larva 4.
- Migrans." <u>Biomedicine.</u> Vol. 36, 1982, pp. 39-42.
  Brunello, F., P. Falagiani, and C. Genchi. "Enzyme Immunoassay (ELISA) for the Detection of Specific IgG Antibodies to Toxocara canis ES Antigens." <u>Boll. Ist. sieroter. Milan</u>. Vol. 65 #1, 1986, pp. 54-60. 5.
- Josephson, S.L., "Toxocariasis", Laboratory Diagnosis of Infectious Diseases Principles and Practices, Vol. 1, 6. 1988, pp. 993-997.

Toxo-G-96 March 2025

<sup>\*</sup>Reference Method refers to a commercially available ELISA.